SCHEDULE: Lytton Group Discloses 9.99% Stake in IN8BIO

Laurence W. Lytton and Lytton-Kambara Foundation report a 9.99% passive beneficial ownership stake in IN8BIO, Inc., including common stock and warrants.

Summary

• Laurence W. Lytton and the Lytton-Kambara Foundation jointly reported beneficial ownership of 984,031 shares of IN8BIO, INC. Common Stock.
• This represents 9.99% of the company's outstanding Common Stock.
• The reported ownership includes 900,000 shares of Common Stock and warrants to purchase 1,092,753 shares of Common Stock.
• The beneficial ownership is subject to a 9.99% limitation, meaning the reporting persons cannot report ownership above this threshold even if their warrants would allow for more.
• The percentage is calculated based on 9,766,132 shares of Common Stock outstanding as of January 12, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a substantial passive investment by a notable individual and foundation suggests confidence in IN8BIO's long-term potential, even if it's a routine disclosure. The inclusion of warrants indicates a potential for future capital infusion upon exercise.

Positives

• A significant investor, Laurence W. Lytton and the Lytton-Kambara Foundation, has taken a substantial 9.99% passive stake in IN8BIO, Inc., indicating confidence in the company's long-term prospects.
• The ownership includes warrants to purchase additional shares, suggesting a potential for increased investment and future capital infusion if the warrants are exercised.

Future Outlook

This Schedule 13G filing does not contain forward-looking statements or guidance from IN8BIO, INC. It solely reports the beneficial ownership stake of Laurence W. Lytton and the Lytton-Kambara Foundation.

Management Comments

• No direct management comments from IN8BIO, INC. are included in this ownership disclosure filing.

Industry Context

StockSavvy.ai notes that a significant passive stake by an individual and a foundation can signal long-term confidence in a company's prospects, particularly in the biotech sector where IN8BIO operates. Such filings often precede or follow other strategic developments, though this filing itself is purely a disclosure of ownership.

Comparison to Industry Standards

• This filing is a standard regulatory disclosure of beneficial ownership and does not contain operational or financial results that can be directly compared to industry benchmarks or specific competitor projects.

Stakeholder Impact

• Shareholders: The presence of a significant, passive investor like Laurence W. Lytton and the Lytton-Kambara Foundation may instill greater confidence in the company's long-term prospects and stability.
• Company Management: Awareness of a substantial shareholder group may influence strategic decisions, though the filing explicitly states the shares are not held for the purpose of changing or influencing control.

Next Steps

• This filing does not outline specific future actions or milestones for IN8BIO, INC.

Key Dates

Recommendation

The disclosure of a significant 9.99% passive stake by Laurence W. Lytton and the Lytton-Kambara Foundation is a positive indicator of investor confidence in IN8BIO, INC. However, as this filing is purely an ownership disclosure and does not provide new operational or financial performance data, a 'hold' recommendation is appropriate. It suggests stability and potential long-term interest but lacks catalysts for an immediate 'buy' or 'sell' decision.

Keywords

IN8BIO, Schedule 13G, Beneficial Ownership, Laurence W. Lytton, Lytton-Kambara Foundation, Common Stock, Warrants, Passive Investment